Clinical trial
Olanzapine in Patients With Borderline Personality Disorder
NCT00091650 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00091650 |
|---|---|
| Title | Olanzapine in Patients With Borderline Personality Disorder |
| Official title | Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine, placebo |
| Enrollment | 300 |
| Start date | Mar 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Sep 27, 2004 |
| Last update posted | Jul 24, 2006 |
| Countries | Belgium, France, Germany, Norway, Portugal, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: